Skip to main content
. 2014 Nov 26;64(12):1961–1971. doi: 10.1136/gutjnl-2014-308041

Figure 5.

Figure 5

Monitoring of viral parameters in HLA-A2/DR1 AAV-HBV-persistent mice. HLA-A2/HLA-DR1 transgenic mice were intravenously injected with PBS or AAV-HBV (day 0) and immunised 1 month later (day 32) with either TG1050 or empty adenovirus. (A) HBV DNA and (B) HBsAg data are represented as mean fold changes (DNA and HBsAg) compared with their respective mean level at day 28 before TG1050 (plain circle curve) or empty Ad (empty circle curve) immunisation or in non-immunised mice (cross curve, for experiment 1 only). Statistical analyses were performed using mixed models and ANOVA for repeated measures. *p<0.05.